Spoerl and colleagues conducted preclinical murine studies with ruxolitinib where they found that JAK1/JAK2 inhibition impaired proliferation of effector T cells, suppressed proinflammatory cytokines, decreased histopathological GVHD grade, and improved overall survival of mice with aGVHD. This evidence concerns the gene JAK1 and graft versus host disease.